1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
Recurrent/Refractory Childhood Hodgkin Lymphoma
Children's Oncology Groupprotein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
150 Active assets in the Recurrent/Refractory Childhood Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CYCLOSPORIN A City of Hope Medical Center | Phase 3 | BBB |
FILGRASTIM Fred Hutchinson Cancer Center | Phase 3 | BBB |
CARMUSTINE VIVUS LLC | Phase 2 | BBB |
Everolimus OHSU Knight Cancer Institute | Phase 2 | BBB |
Cytosin-Arabinosid Therapeutic Advances in Childhood Leukemia Consortium | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →